March 17 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 308.2 million euro ($340.6 million) in 2021, up 7%, the company said on Thursday, citing unaudited data.
Consolidated revenue increased to 1.566 billion euro in 2021 from 1.535 billion euro in the previous year, Krka said in a filing with the Ljubljana Stock Exchange.
The gross profit of Krka group in 2021 fell 2% to 891.2 million euro, while consolidated EBITDA amounted to 463.6 million euro, down 8%.
The Krka group allocated 66.4 million euro to investments last year, of which 49.5 million euro to the controlling company.
Eastern Europe generated the highest sales within the group, of 547.8 million euro, or 35.1% of total sales. Sales in Eastern Europe rose 6% in 2021.
Next came Central Europe, where sales revenue increased 3% to 351.5 million euro, or 22.5% of total sales. Western Europe followed with sales of 305.2 million euro, down 11% over 2020 and 19.6% of total.
Sales in Southeast Europe grew 5% to 209.2 million euro, whereas sales in the Overseas Markets segment increased 18% to 53.7 million euro.
Sales in Slovenia increased to 92.9 million euro, up 5% on the year. They contributed 6.0% of total Krka group sales.
The company's shares traded up 6.91% at 92.80 euro by 0950 CET on Thursday on the Ljubljana bourse.
($ = 0.825717 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here